Supernus Pharmaceuticals, Inc. (SUPN)
Automate Your Wheel Strategy on SUPN
With Tiblio's Option Bot, you can configure your own wheel strategy including SUPN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SUPN
- Rev/Share 3405.5367
- Book/Share 18560.851
- PB 0.0028
- Debt/Equity 0.0299
- CurrentRatio 1.7962
- ROIC -0.0553
- MktCap 2881303116.0
- FreeCF/Share 3.2866
- PFCF 15.5021
- PE -152.2904
- Debt/Assets 0.0221
- DivYield 0
- ROE -0.0001
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 5
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | SUPN | Piper Sandler | Neutral | Overweight | -- | $65 | Oct. 9, 2025 |
| Upgrade | SUPN | Cantor Fitzgerald | Neutral | Overweight | -- | $42 | July 30, 2025 |
| Downgrade | SUPN | Cantor Fitzgerald | Overweight | Neutral | $57 | $36 | Feb. 19, 2025 |
| Initiation | SUPN | Cantor Fitzgerald | -- | Overweight | -- | $57 | Jan. 6, 2025 |
| Downgrade | SUPN | Piper Sandler | Overweight | Neutral | $41 | $36 | Sept. 11, 2024 |
News
Supernus Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - SUPN
Published: February 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
Read More
SUPN ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Supernus Pharmaceuticals, Inc.
Published: February 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
Read More
BREAKING: Supernus Pharmaceuticals, Inc. Shares Down 14%; Investors Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) for potential securities law violations. Investors who have lost money in their Supernus Pharmaceuticals, Inc. investment should contact the firm to learn more about how they might recover those losses.
Read More
Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
ROCKVILLE, Md., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the fourth quarter and full year of 2024 after the market closes on Tuesday, February 25, 2025.
Read More
About Supernus Pharmaceuticals, Inc. (SUPN)
- IPO Date 2012-05-01
- Website https://www.supernus.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Jack A. Khattar
- Employees 674